Accretion Nutraveda IPO Set to List Today; GMP Signals Neutral Debut

Shares of Accretion Nutraveda Ltd. are scheduled to debut on the BSE SME platform today, 4 February 2026, after a moderately subscribed public issue that closed last month, according to a report from The Economic Times.

📌 IPO Overview & Price Band

• The company’s IPO was open for subscription from 28 January 2026 to 30 January 2026. 
• It was entirely a fresh issue, offering 19.2 lakh shares. 
• The price band for investors was fixed at ₹122–₹129 per share. 
• At the upper end of the price band, the issue size was valued at approximately ₹24.77 crore.
  

📈 Subscription Details

• The IPO was moderately subscribed overall, with total subscription at 1.83 times the shares on offer. 
• Retail investors showed strong interest, subscribing 2.19 times. 
• Non-institutional investors (NIIs) subscribed about 2.08 times, while qualified institutional buyers (QIBs) were modest at 1.01 times. 
• Ahead of the IPO, the company raised around ₹7.02 crore from anchor investors.
  

📍 Grey Market Premium & Listing Expectations

• In the grey market, the grey market premium (GMP) stood at zero ahead of listing, indicating that traders expect the share to list close to its upper price band of ₹129 per share. 
• The flat GMP suggests a neutral market sentiment, reflecting cautious expectations by investors about listing gains.
  

📊 Business & Financial Snapshot

Accretion Nutraveda operates as a Contract Development and Manufacturing Organization (CDMO) specialising in Ayurvedic and nutraceutical products including:

• Tablets 
• Capsules 
• Liquids 
• Powders 
• Topical preparations
  …for both domestic and overseas markets including Sri Lanka, Singapore and the United States.
  

For the period ended 30 September 2025, the company reported:

• Total income: ₹14.07 crore 
• Profit after tax: ₹2.33 crore
  …compared with ₹5.20 crore in revenue and ₹0.82 crore in profit for the previous year.
  

📝 What Investors Are Watching

• Today’s listing performance will be closely watched, especially given the flat GMP, which indicates limited market enthusiasm ahead of debut. 
• Market participants note that SME IPO listings can be volatile on debut, with outcomes largely driven by investor demand on the day of listing.
  

Overall, while Accretion Nutraveda’s IPO attracted decent subscription from retail investors, the neutral grey market premium points to tempered expectations for listing-day gains when the stock begins trading on the BSE SME platform.